GO:0017129 triglyceride binding: Mechanism & Genes

Triglyceride binding (GO:0017129) is a molecular function that describes the selective, non-covalent interaction of a protein or other macromolecule with a triester of glycerol, commonly referred to as a triacylglycerol. This function is fundamental to lipid biology because triglycerides are the principal storage form of metabolic energy and the core cargo of triglyceride-rich lipoproteins such as chylomicrons and very-low-density lipoproteins [1,7]. Proteins that bind triglycerides participate in lipoprotein assembly, secretion, intravascular lipolysis, receptor-mediated uptake and intracellular lipid droplet dynamics [1,7]. Consequently, the study of triglyceride binding is central to understanding dyslipidemia, atherosclerosis, hepatic steatosis and related cardiometabolic disorders [1,6,8]. From a research perspective, triglyceride binding is not a single pathway but a functional annotation that unifies diverse proteins, including apolipoproteins, lipases, lipid transfer proteins and membrane receptors [1,7]. For example, apolipoprotein B (APOB) binds triglyceride during the assembly of very-low-density lipoproteins, while apolipoprotein C-III (APOC3) modulates the clearance of triglyceride-rich lipoproteins. Genetic and pharmacological studies have shown that reducing APOC3 function lowers plasma triglycerides and cardiovascular risk, underscoring the clinical relevance of triglyceride-binding interactions. Modern functional genomics has begun to map the genes required for triglyceride binding and uptake. A CRISPR/Cas9 library screen in Hep3B cells identified heparan sulfate proteoglycan receptors as key mediators of triglyceride-rich lipoprotein binding, demonstrating that this molecular function can be dissected at scale. Complementary work on PNPLA3-I148M revealed that a single amino acid change can create a neomorphic protein that interferes with two primary hepatic triglyceride clearance pathways, directly linking triglyceride binding and hydrolysis to nonalcoholic fatty liver disease. These examples illustrate why GO:0017129 is a valuable annotation for interpreting lipid-related datasets and for designing mechanistic experiments.

In the Gene Ontology, triglyceride binding (GO:0017129) is defined as binding to a triester of glycerol. A triester of glycerol is a glycerol molecule in which all three hydroxyl groups are esterified with fatty acids, forming a triglyceride (triacylglycerol). This molecular function therefore describes the ability of a protein or macromolecule to recognize and physically associate with triglyceride molecules through non-covalent interactions. The synonym triacylglycerol binding is used interchangeably. This term is a molecular_function annotation and does not imply catalysis; it specifically captures binding, which may serve structural, transport, signaling or substrate-presentation roles in lipid metabolism [1,7].

Triglyceride binding is important because it governs how cells and organisms handle their most energy-dense lipid cargo. Proteins that bind triglycerides determine whether these molecules are packaged into lipoproteins for secretion, stored in lipid droplets, hydrolyzed for fatty acid release or taken up by target tissues [1,7]. Dysregulation of these binding events contributes directly to hypertriglyceridemia, atherosclerosis and hepatic steatosis, making GO:0017129 a functionally meaningful annotation for cardiovascular and metabolic research [1,6,8]. Moreover, because triglyceride binding can be targeted pharmacologically, as shown by antisense inhibition of APOC3, understanding the underlying molecular interactions has direct therapeutic implications.

The following genes and proteins represent major triglyceride-binding or triglyceride-handling factors supported by the verified literature.

Triglyceride binding and the broader process of triglyceride metabolism are regulated at multiple levels. Transcriptionally, SREBP-1c activates lipogenic genes such as DGAT1 and DGAT2 in response to glycerol kinase signaling, promoting triglyceride synthesis and packaging. Hormonally, ZNF638 regulates triglyceride metabolism via ANGPTL8 in an estrogen-dependent manner, demonstrating sex-hormone control of lipid handling. Post-translationally, GPIHBP1 stabilizes lipoprotein lipase and facilitates its transport to the capillary lumen, while APOC3 inhibits lipoprotein lipase activity [1,7]. Nutritional state also plays a role: Rab30 facilitates lipid homeostasis during fasting, linking vesicular trafficking to triglyceride mobilization. These regulatory layers ensure that triglyceride binding and utilization are matched to energy demand and hormonal signals.

Elevated plasma triglycerides are an independent risk factor for atherosclerotic cardiovascular disease. Apolipoproteins such as APOC3 and APOA5 directly modulate triglyceride-rich lipoprotein metabolism, and genetic or pharmacological reduction of APOC3 lowers both triglycerides and cardiovascular risk [1,6]. The approval of olezarsen, an antisense oligonucleotide targeting APOC3, validates triglyceride-binding proteins as therapeutic targets. GPIHBP1 dysfunction causes severe hypertriglyceridemia by impairing lipoprotein lipase-mediated lipolysis.

Hepatic triglyceride accumulation is the hallmark of nonalcoholic fatty liver disease. PNPLA3-I148M is a neomorphic variant that interferes with two primary hepatic triglyceride clearance pathways, promoting steatosis and liver injury. Glycerol kinase drives hepatic de novo lipogenesis and triglyceride synthesis by activating SREBP-1c and upregulating DGAT1/2, providing another mechanistic link to fatty liver. These findings position triglyceride binding and hydrolysis as central to NAFLD pathogenesis.

Triglyceride binding and transport are integrated with systemic metabolic control. ZNF638 regulates triglyceride metabolism via ANGPTL8 in an estrogen-dependent manner, linking hormonal status to lipid homeostasis. Rab30 facilitates lipid homeostasis during fasting, connecting vesicular trafficking to energy mobilization. Dysregulation of these pathways contributes to the clustering of metabolic abnormalities known as metabolic syndrome.

Genome-wide CRISPR/Cas9 knockout libraries enable unbiased discovery of genes required for triglyceride binding and uptake. A screen in Hep3B cells identified heparan sulfate proteoglycan receptors as mediators of triglyceride-rich lipoprotein binding, demonstrating the power of this approach. Libraries can be designed to target all protein-coding genes or focused on lipid-related pathways.

Mass spectrometry-based lipidomics and enzymatic triglyceride assays quantify cellular and plasma triglyceride levels, providing functional readouts for triglyceride-binding perturbations. These methods are essential for validating CRISPR models of genes such as PNPLA3, APOC3 and glycerol kinase [2,6,8].

In vitro binding assays, including liposome co-flotation, surface plasmon resonance and isothermal titration calorimetry, measure direct interactions between purified proteins and triglyceride-containing particles. Such assays have been used to characterize apolipoprotein and GPIHBP1 binding to lipoproteins [1,7].

RNA-seq and proteomics reveal how genetic perturbations alter lipid metabolic networks. For example, glycerol kinase activation upregulates SREBP-1c and DGAT1/2 expression, which can be monitored by transcriptomic profiling. Proteomic analysis of lipoprotein fractions can identify novel triglyceride-binding proteins.

Researchers studying triglyceride binding-related genes often need to determine whether a candidate gene is causally involved in lipid transport, storage or clearance. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional validation of triglyceride-binding proteins and their disease relevance.

Triglyceride binding (GO:0017129) is a fundamental molecular function that underpins lipid transport, lipoprotein assembly, intravascular lipolysis and cellular lipid uptake. Proteins such as APOB, APOC3, GPIHBP1 and PNPLA3 mediate these interactions, and their dysfunction contributes to hypertriglyceridemia, atherosclerosis and nonalcoholic fatty liver disease [1,6,7,8]. The integration of CRISPR functional genomics with lipidomics and proteomics has accelerated the discovery of novel triglyceride-binding factors, as exemplified by the identification of heparan sulfate proteoglycan receptors. Continued research into this GO term will inform new therapeutic strategies for cardiometabolic disease.